research use only

DC661 Autophagy inhibitor

Name: DC661
Brand: Selleck Chemicals
SKU: S8808
Availability: InStock
Rating: 5 (16 reviews)

Cat.No.S8808

DC661 is a potent palmitoyl protein thioesterase 1 (PPT1) inhibitor. DC661 is capable of deacidifying the lysosome and inhibiting autophagy significantly better than HCQ. DC661 induces apoptosis.

Chemical Structure

Molecular Weight: 552.58

Jump to

Quality Control

Batch: S880801 Ethanol]49 mg/mL]false]DMSO]7 mg/mL]false]Water]Insoluble]false Purity: 99.7%

Cited in Nature Medicine for its top-tier quality
COA
SDS
Datasheet

99.7

Related Targets	CXCR Nrf2 Mitophagy LRRK2 ULK FKBP Heme Oxygenase LC3 cGAS Cell wall
Other Autophagy Products	Resveratrol (trans-Resveratrol) Spautin-1 PIK-III Lys05 Autophinib SMER28 EAD1 Flubendazole EN6 ROC-325

Solubility

In vitro
Batch:

Ethanol : 49 mg/mL

DMSO : 7 mg/mL (12.66 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	2%DMSO 1 40%PEG300 2 5%Tween80 3 53%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.200mg/ml (0.36mM)	Taking the 1 mL working solution as an example, add 20 μL of clarified DMSO stock solution of 10 mg/ml to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify it; then continue to add 530 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	552.58	Formula	C₃₁H₃₉Cl₂N₅	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	1872387-43-3	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	CN(CCCCCCNC1=C2C=CC(=CC2=NC=C1)Cl)CCCCCCNC3=C4C=CC(=CC4=NC=C3)Cl

Mechanism of Action

Targets/IC₅₀/Ki	Autophagy
In vitro	Treatment of melanoma cells with DC661 results in a more striking accumulation of the autophagic vesicle marker LC3B-II at lower concentrations compared with either Lys05 or HCQ, reflecting more pronounced accumulation of autophagic vesicles at concentrations between 0.1 and 10 μmol/L. All cells die at concentrations above 10 μmol/L for this compound in contrast to Lys05 and HCQ. Compared with HCQ or Lys05, this compound treatment induces a significantly more potent inhibition of autophagic flux in melanoma cells expressing the mCherry-eGFP-LC3B reporter, and significantly higher levels of free GFP in melanoma cells expressing GFP-LC3B. This compound treatment resulted in significantly greater lysosomal deacidification compared with either HCQ or Lys05. The IC50 of this chemical in 72-hour MTT assays is 100-fold lower than that of HCQ across multiple cancer cell lines including colon and pancreas cancer cell lines. This compound suppresses long-term clonogenic growth of melanoma cells more effectively and induces significantly more apoptosis than Lys05, HCQ, or combined BRAF and MEK inhibition in BRAF-mutant melanoma cells.
In vivo	Treatment with the reduced dose (3 mg/kg, i.p.) of DC661 in a HT29 xenograft results in a significant reduction in tumor volume and almost complete suppression of daily tumor growth rate compared with control mice without significantly affecting mouse weight.
References	[1] https://pubmed.ncbi.nlm.nih.gov/30442709/

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Can you provide any information on how to formulate it for in vivo IP injection?

Answer:
Formula: 5% Stock solution (20 mg/ml)+40% PEG 300+5% Tween80+50% ddH2O, concentration:1mg/ml.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):